These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9758357)

  • 1. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation.
    Ruutu T; Hermans J; van Biezen A; Niederwieser D; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1998 Sep; 22(6):614-5. PubMed ID: 9758357
    [No Abstract]   [Full Text] [Related]  

  • 2. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT.
    Ruutu T; Niederwieser D; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1997 Apr; 19(8):759-64. PubMed ID: 9134165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Digestive manifestations of graft-versus-host disease (GVHD) in bone marrow transplantation, organ transplantation and transfusion].
    Li V; Molina L; Michallet M; Hostein J
    Gastroenterol Clin Biol; 1992; 16(1):29-36. PubMed ID: 1537479
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.
    Hervé P; Racadot E; Wijdenes J; Flesch M; Tiberghien P; Bordigoni P; Holler E; Powles M; Bourdeau M; Wilmer E
    Bone Marrow Transplant; 1991; 7 Suppl 2():149. PubMed ID: 1878688
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal rhabdomyolysis as a complication of bone marrow transplantation.
    Volin L; Järventie G; Ruutu T
    Bone Marrow Transplant; 1990 Jul; 6(1):59-60. PubMed ID: 2390634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children.
    Peters C; Minkov M; Gadner H; Klingebiel T; Vossen J; Locatelli F; Cornish J; Ortega J; Bekasi A; Souillet G; Stary J; Niethammer D; ;
    Bone Marrow Transplant; 2000 Aug; 26(4):405-11. PubMed ID: 10982287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD.
    Bertz H; Afting M; Kreisel W; Duffner U; Greinwald R; Finke J
    Bone Marrow Transplant; 1999 Dec; 24(11):1185-9. PubMed ID: 10642806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
    Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
    Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
    Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated nocardiosis in a bone marrow transplant recipient with chronic GVHD.
    Bhave AA; Thirunavukkarasu K; Gottlieb DJ; Bradstock K
    Bone Marrow Transplant; 1999 Mar; 23(5):519-21. PubMed ID: 10100569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical acute graft-versus-host disease.
    Shin J; Hong W; Song H; Choi G; Kim YC
    Am J Dermatopathol; 2007 Dec; 29(6):576-7. PubMed ID: 18032957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal photopheresis in graft-versus-host disease.
    Carcagnì MR; De Aloe G; D'Ascenzo G; Rubegni P; Fimiani M
    J Dtsch Dermatol Ges; 2008 Jun; 6(6):451-7. PubMed ID: 18177413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autogous bone marrow transplantation for childhood acute myeloid leukemia--a European survey. EBMT Working Party on ABMT.
    Herve P; Labopin M; Plouvier E; Palut P; Tiberghien P; Gorin N
    Bone Marrow Transplant; 1991; 8 Suppl 1():76-9. PubMed ID: 1760652
    [No Abstract]   [Full Text] [Related]  

  • 18. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
    Margolis J; Vogelsang G
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.